References
- Gurwitz D , ZikaE, HopkinsMM, GaisserS, IbarretaD. Pharmacogenetics in Europe: barriers and opportunities. Pub. Health Genomics12 , 134–141 (2009).
- Gurbel PA , BlidenKP, HiattBL et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23) , 2908–2913 (2003).
- Kushner FG , HandM, SmithSC Jr et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation120 , 2271–2306 (2009).
- Holmes DR Jr, Dehmer GJ, Kaul S, Leifer D, O‘Gara PT, Stein CM. ACCF/AHA clopidogrel clinical alert: approaches to the FDA “Boxed Warning”: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the American Heart Association. J. Am. Coll. Cardiol.56(4) , 321–341 (2010).
- Wang TH , BhattDL, TopolEJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J.27(6) , 647–654 (2006).
- Simon T , VerstuyftC, Mary-KrauseM et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 360(4) , 363–375 (2009).
- Shuldiner AR , O‘ConnellJR, BlidenKP et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302(8) , 849–857 (2009).
- Mega JL , CloseSL, WiviottSD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4) , 354–362 (2009).
- Mega JL , SimonT, ColletJP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI. A meta-analysis. JAMA 304(16) , 1821–1830 (2010).
- Bouman HJ , SchomigE, van Werkum JW et al. Paraoxonase-1 is a major determinant of clopidogrel efficacy. Nat. Med.17(1) , 110–116 (2011).
- Jackevicius CA , ChouMM, RossJS, ShahND, KrumholzHM. Generic atorvastatin and health care costs. N. Engl. J. Med.366(15) , 1451–1451 (2012).
- Ruaño G , ThompsonPD, KaneJP et al. Physiogenomic analysis of statin-treated patients: domain specific counter effects within the ACACB gene on LDL cholesterol? Pharmacogenomics 11 , 959–971 (2010).
- Ruaño G , WindemuthA, WuAH et al. Mechanisms of statin induced myalgia assessed by physiogenomic associations. Atherosclerosis 218(2) , 451–456 (2011).
- Ruaño G , ThompsonPD, WindemuthA et al. Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis. Pharmacogenomics 6(8) , 865–872 (2005).
- Ruaño G , ThompsonPD, WindemuthA et al. Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle Nerve 36(3) , 329–335 (2007).
- Ruaño G , GoetheJW, CaleyC et al. Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients. Mol. Psychiatry 12 , 474–482 (2007).
- Windemuth A , de Leon J, Goethe JW et al. Validation of candidate genes associated with cardiovascular risk factors in psychiatric patients. Prog. Neuropsychopharmacol. Biol. Psychiatry36(2) , 213–219 (2012).
- Furiak NM , Ascher-SvanumH, KleinRW. Cost–effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. Cost Eff. Res. Alloc.7 , 4 (2009).
- Frueh FW . Real-world clinical effectiveness, regulatory transparency and payer coverage: three ingredients for translating pharmacogenomics into clinical practice. Pharmacogenomics11(5) , 657–660 (2010).
- Epstein RS , MoyerTP, AubertRE et al. Warfarin genotyping reduces hospitalization rates. Results from the MM-WES (Medco-Mayo warfarin effectiveness study). J. Am. Coll. Cardiol. 55 , 2804–2812 (2010).
▪ Websites
- Medical data provider IMS Health. www.imshealth.com/portal/site/ims (Accessed 14April2012)
- Drug Patent Watch Expiration Bulletin, 2010–11. www.DrugPatentWatch.com/newsletter (Accessed 14April2012)
- Drugs@FDA. FDA approved drug products. www.accessdata.fda.gov/Scripts/cder/DrugsatFDA/index.cfm (Accessed 14April2012)
- Medco‘s New Idea: PGx Program for Generics to Dispense ‘Smarter‘ Treatments and Increase Savings. Pharmacogenomics Reporter. October 2009. www.genomeweb.com/dxpgx/medcos-new-idea-pgx-program-generics-dispense-smarter-treatments-and-increase-sa (Accessed 14April2012)
- The Case for Personalized Medicine, 3rd Edition. Personalized Medicine Coalition. www.personalizedmedicinecoalition.org/sites/default/files/files/Case_for_PM_3rd_edition.pdf (Accessed 14April2012)